Combination therapy with cisplatin, 5'-deoxy-5-fluorouridine (5'-DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastric cancer - PubMed

Affiliations

• PMID: 21594354
• DOI: 10.3892/or.3.2.255

Combination therapy with cisplatin, 5'-deoxy-5-fluorouridine (5'-DFUR) and mitomycin (MMC) in patients with inoperable, advanced gastric cancer

W Koizumi et al. Oncol Rep. 1996 Mar.

Abstract

The optimal dose of cisplatin (CDDP) for combination chemotherapy for the treatment of inoperable, advanced gastric cancer has yet to be established. We therefore performed a randomized study to compare the therapeutic usefulness of two dose levels of cisplatin. 5'-deoxy-5-fluorouridine (5'-DFUR 1,400 mg/m(2)/d) was given orally on days 1 to 4 and 15 to 18. Mitomycin C (MMC, 5.75 mg/m(2)/d) was injected intravenously on day 5. In addition, 80 mg/m2/d of CDDP (regimen A) or 60 mg/m(2)/d of CDDP (regimen B) was given by 2-h intravenous drip infusion on day 5. This treatment cycle was repeated every four weeks. Fifty-six patients were enrolled. Clinical response was evaluated in 32 patients (regimen A, 16 patients; regimen B? 16 patients) with measurable lesions. The response rate was significantly higher with regimen A (9 PR/16, 56.3%) than with regimen B (3 PR/16, 18.9%) (p=0.028, chi(2) test). Median survival was slightly but not significantly longer with regimen A (7.4 months) than with regimen B (6.3 months). Drug toxicity included myelosuppression and gastrointestinal symptoms, but there were no serious adverse reactions or differences in safety between the treatment regimens. Regimen A was associated with a high response rate and low toxicity. The optimal dose of CDDP in combination with 5'-DFUR and MMC for the treatment of advanced gastric cancer is regarded to be 80 mg/m(2).

Similar articles

• Randomized phase II study comparing mitomycin, cisplatin plus doxifluridine with cisplatin plus doxifluridine in advanced unresectable gastric cancer.

  Koizumi W, Fukuyama Y, Fukuda T, Akiya T, Hasegawa K, Kojima Y, Ohno N, Kurihara M. Koizumi W, et al. Anticancer Res. 2004 Jul-Aug;24(4):2465-70. Anticancer Res. 2004. PMID: 15330199 Clinical Trial.

• A phase II study of combination therapy with 5'-deoxy-5-fluorouridine and cisplatin in the treatment of advanced gastric cancer with primary foci.

  Koizumi W, Kurihara M, Sasai T, Yoshida S, Morise K, Imamura A, Akazawa S, Betsuyaku T, Ohkubo S, Takahashi H, et al. Koizumi W, et al. Cancer. 1993 Aug 1;72(3):658-62. doi: 10.1002/1097-0142(19930801)72:3<658::aid-cncr2820720306>3.0.co;2-k. Cancer. 1993. PMID: 8334621 Clinical Trial.

• [Combination chemotherapy of TS-1 +cisplatin for inoperable gastric cancer].

  Koizumi W, Tanabe S, Higuchi K, Sasaki T, Nakayama N, Nagaba S, Azuma M, Shimoda T, Nishimura K, Nakatani K, Saigenji K. Koizumi W, et al. Gan To Kagaku Ryoho. 2004 Nov;31(12):1957-61. Gan To Kagaku Ryoho. 2004. PMID: 15570920 Review. Japanese.

• [Process of making a protocol for advanced gastric cancer chemotherapy--using 5'-DFUR+CDDP as an example].

  Kurihara M. Kurihara M. Gan To Kagaku Ryoho. 1993 Dec;20(16):2447-53. Gan To Kagaku Ryoho. 1993. PMID: 8279840 Review. Japanese.

Cited by

• Chemotherapy for advanced gastric cancer.

  Wagner AD, Syn NL, Moehler M, Grothe W, Yong WP, Tai BC, Ho J, Unverzagt S. Wagner AD, et al. Cochrane Database Syst Rev. 2017 Aug 29;8(8):CD004064. doi: 10.1002/14651858.CD004064.pub4. Cochrane Database Syst Rev. 2017. PMID: 28850174 Free PMC article. Review.

LinkOut - more resources

• Full Text Sources

  • Ingenta plc
  • Spandidos Publications

• Research Materials

  • NCI CPTC Antibody Characterization Program